Currently, the only targeted immunotherapy regimens for GC are Human epidermal growth factor receptor 2 (HER-2) monoclonal antibody, programmed death 1 (PD-1) monoclonal antibody and programmed death ligand 1 (PD-L1) monoclonal antibody. This evidence concerns the gene CD274 and gastric cancer.